Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2023-08-15 00:00:00 ET · period of report 2023-08-12 · accession 0001628280-23-029599 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-15 | 2023-08-12 | NAGE | Gerber Brianna | CFO | M - OptEx | — | +22.4K | 22.4K | New | — |
| D | 2023-08-15 | 2023-08-12 | NAGE | Gerber Brianna | CFO | M - OptEx | $0.00 | -22.4K | 44.9K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-12 | M | A | 22,436 | — | 22,436 | D | — | — | (F2) On August 12, 2022, the Reporting Person was awarded RSUs which will be settled in shares of Common Stock when vested. |
| 2 | Derivative | Restricted Stock Unit | 2023-08-12 | M | D | 22,436 | $0.00 | 44,872 | D | — · — to — | 22,436 Common Stock | (F2) On August 12, 2022, the Reporting Person was awarded RSUs which will be settled in shares of Common Stock when vested. (F4) RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023. |